By Connor Hart
Artiva Biotherapeutics named Subhashis Banerjee as its chief medical officer, succeeding Thorsten Graef, who will continue to serve the company as a strategic adviser.
Banerjee is a trained rheumatologist and immunologist with more than two decades of clinical development experience in autoimmune diseases, the San Diego-based company said Tuesday.
His appointment will help the company progress the clinical development of its treatment of B-cell driven autoimmune diseases, Chief Executive Fred Aslan said.
Prior to joining Artiva, Banerjee helmed Bristol Myers Squibb's rheumatology and dermatology global development arm. Previously, he held an executive position at Vyne Therapeutics.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 08, 2025 16:57 ET (20:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。